



PRESS RELEASE • PRESS RELEASE • PRESS RELEASE

NEOVACS TO PRESENT AT BIO EUROPE SPRING 2015

Paris, February 19, 2015 – NEOVACS (Alternext Paris: ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, announced today that the Company will be presenting at the BIO Europe Spring 2015 Partnering Conference to be held in Paris, Porte de Versailles, on March 9-11, 2015.

The spring edition of BIO Europe Conference attracts thousands of representatives from the biotechnology and pharmaceutical industries.

Miguel Sieler, CEO of Neovacs, will present on March 10, 2015 at 4:30 pm C.E.T. Neovacs will be attending the three-day conference with a booth.

About Neovacs

Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFN α -Kinoid, an immunotherapy being developed for the indication of lupus. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.

For more information on Neovacs, visit www.neovacs.fr

Contacts

NEOVACS

Nathalie Trépo
+33 (0)1 53 10 93 00
ntrepo@neovacs.com

Press – Financial Communications- Publicis

Stéphanie Tabouis
+33 (0) 1 44 82 46 35
stephanie.tabouis@consultants.publicis.fr

Investor Relations – Financial Communications Germany – MC Services

Raimund Gabriel

+49-89-210228-30

Raimund.Gabriel@mc-services.eu

Press – U.S. Inquiries – The Ruth Group

Melanie Sollid-Penton

1.646.536.7023

msollid@theruthgroup.com